Status:
COMPLETED
Retrospective, Non-interventional Study of Depo-Eligard®.
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
Study will evaluate the real-world effectiveness of Depo-Eligard® after six months of treatment
Detailed Description
The study will provide data on the tolerance, safety and acceptance of Depo-Eligard® (leuproreline acetate) when used in routine clinical practice. Data on efficacy parameters such as testosterone, PS...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients having been prescribed Depo-Eligard® in accordance with the terms of the marketing authorization
- Patients on treatment with Depo-Eligard® for at least six months
- Written consent has been obtained
Exclusion
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT00811876
Start Date
September 1 2008
End Date
December 1 2009
Last Update
January 22 2010
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Antwerp, Belgium, 2060
2
Berlaar, Belgium, 2590
3
Bornem, Belgium, 2880
4
Brussels, Belgium, 1020